Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared a post on X:
“Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.”
Authors: Lorenza Rimassa, et al.
